Logo image of AMRX

AMNEAL PHARMACEUTICALS INC (AMRX) Stock Fundamental Analysis

NASDAQ:AMRX - US03168L1052 - Common Stock

9.37 USD
+0.01 (+0.11%)
Last: 8/28/2025, 2:20:47 PM
Fundamental Rating

5

Overall AMRX gets a fundamental rating of 5 out of 10. We evaluated AMRX against 193 industry peers in the Pharmaceuticals industry. AMRX has a medium profitability rating, but doesn't score so well on its financial health evaluation. AMRX is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

AMRX had positive earnings in the past year.
In the past year AMRX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: AMRX reported negative net income in multiple years.
AMRX had a positive operating cash flow in each of the past 5 years.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

The Return On Assets of AMRX (0.10%) is better than 79.79% of its industry peers.
The Return On Invested Capital of AMRX (11.52%) is better than 88.08% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMRX is significantly below the industry average of 15.38%.
The 3 year average ROIC (7.98%) for AMRX is below the current ROIC(11.52%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.1%
ROE N/A
ROIC 11.52%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300 -400

1.3 Margins

AMRX's Profit Margin of 0.12% is fine compared to the rest of the industry. AMRX outperforms 79.79% of its industry peers.
AMRX has a better Operating Margin (13.31%) than 84.46% of its industry peers.
AMRX's Operating Margin has improved in the last couple of years.
AMRX's Gross Margin of 37.67% is in line compared to the rest of the industry. AMRX outperforms 59.07% of its industry peers.
In the last couple of years the Gross Margin of AMRX has grown nicely.
Industry RankSector Rank
OM 13.31%
PM (TTM) 0.12%
GM 37.67%
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
Compared to 1 year ago, AMRX has less shares outstanding
AMRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AMRX has been reduced compared to a year ago.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 1.63, we must say that AMRX is in the distress zone and has some risk of bankruptcy.
AMRX's Altman-Z score of 1.63 is fine compared to the rest of the industry. AMRX outperforms 62.18% of its industry peers.
The Debt to FCF ratio of AMRX is 9.66, which is on the high side as it means it would take AMRX, 9.66 years of fcf income to pay off all of its debts.
AMRX has a Debt to FCF ratio of 9.66. This is in the better half of the industry: AMRX outperforms 78.76% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 9.66
Altman-Z 1.63
ROIC/WACC1.03
WACC11.14%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

AMRX has a Current Ratio of 1.43. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.43, AMRX is doing worse than 68.39% of the companies in the same industry.
A Quick Ratio of 0.88 indicates that AMRX may have some problems paying its short term obligations.
AMRX has a Quick ratio of 0.88. This is in the lower half of the industry: AMRX underperforms 76.68% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.88
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.46%, which is quite good.
The Earnings Per Share has been growing by 10.63% on average over the past years. This is quite good.
AMRX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.73%.
AMRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.43% yearly.
EPS 1Y (TTM)17.46%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%56.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%3.24%

3.2 Future

The Earnings Per Share is expected to grow by 11.95% on average over the next years. This is quite good.
The Revenue is expected to grow by 0.60% on average over the next years.
EPS Next Y31.02%
EPS Next 2Y25.98%
EPS Next 3Y24.22%
EPS Next 5Y11.95%
Revenue Next Year8.32%
Revenue Next 2Y7.29%
Revenue Next 3Y7.7%
Revenue Next 5Y0.6%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

AMRX is valuated correctly with a Price/Earnings ratio of 12.66.
Based on the Price/Earnings ratio, AMRX is valued cheaper than 88.60% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.14, AMRX is valued rather cheaply.
A Price/Forward Earnings ratio of 10.18 indicates a reasonable valuation of AMRX.
84.97% of the companies in the same industry are more expensive than AMRX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of AMRX to the average of the S&P500 Index (22.80), we can say AMRX is valued rather cheaply.
Industry RankSector Rank
PE 12.66
Fwd PE 10.18
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaper than 90.67% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMRX is valued cheaply inside the industry as 90.16% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.25
EV/EBITDA 8.17
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of AMRX may justify a higher PE ratio.
A more expensive valuation may be justified as AMRX's earnings are expected to grow with 24.22% in the coming years.
PEG (NY)0.41
PEG (5Y)1.19
EPS Next 2Y25.98%
EPS Next 3Y24.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (8/28/2025, 2:20:47 PM)

9.37

+0.01 (+0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-07 2025-11-07/bmo
Inst Owners39.86%
Inst Owner Change4.61%
Ins Owners46.58%
Ins Owner Change-0.68%
Market Cap2.94B
Analysts82
Price Target12.24 (30.63%)
Short Float %3.18%
Short Ratio2.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.21%
Min EPS beat(2)40.06%
Max EPS beat(2)40.37%
EPS beat(4)3
Avg EPS beat(4)18.44%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)29.41%
EPS beat(12)10
Avg EPS beat(12)26.58%
EPS beat(16)11
Avg EPS beat(16)18.46%
Revenue beat(2)0
Avg Revenue beat(2)-4.66%
Min Revenue beat(2)-4.71%
Max Revenue beat(2)-4.6%
Revenue beat(4)1
Avg Revenue beat(4)-2.31%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)4
Avg Revenue beat(8)-0.35%
Revenue beat(12)7
Avg Revenue beat(12)0.09%
Revenue beat(16)8
Avg Revenue beat(16)-0.43%
PT rev (1m)2.13%
PT rev (3m)4.35%
EPS NQ rev (1m)-8.57%
EPS NQ rev (3m)-4%
EPS NY rev (1m)5.67%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)-1.07%
Revenue NQ rev (3m)8.33%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-0.58%
Valuation
Industry RankSector Rank
PE 12.66
Fwd PE 10.18
P/S 1.03
P/FCF 11.25
P/OCF 8.38
P/B N/A
P/tB N/A
EV/EBITDA 8.17
EPS(TTM)0.74
EY7.9%
EPS(NY)0.92
Fwd EY9.82%
FCF(TTM)0.83
FCFY8.89%
OCF(TTM)1.12
OCFY11.93%
SpS9.08
BVpS-0.36
TBVpS-4.33
PEG (NY)0.41
PEG (5Y)1.19
Profitability
Industry RankSector Rank
ROA 0.1%
ROE N/A
ROCE 16.4%
ROIC 11.52%
ROICexc 11.84%
ROICexgc 23.31%
OM 13.31%
PM (TTM) 0.12%
GM 37.67%
FCFM 9.17%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexcg growth 3Y25.12%
ROICexcg growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 9.66
Debt/EBITDA 3.99
Cap/Depr 36.48%
Cap/Sales 3.14%
Interest Coverage 1.59
Cash Conversion 56.16%
Profit Quality 7750.49%
Current Ratio 1.43
Quick Ratio 0.88
Altman-Z 1.63
F-Score7
WACC11.14%
ROIC/WACC1.03
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.46%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%56.25%
EPS Next Y31.02%
EPS Next 2Y25.98%
EPS Next 3Y24.22%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%3.24%
Revenue Next Year8.32%
Revenue Next 2Y7.29%
Revenue Next 3Y7.7%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year11.33%
EBIT Next 3Y10.45%
EBIT Next 5Y3.87%
FCF growth 1Y129.81%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y76.74%
OCF growth 3Y6.86%
OCF growth 5Y180.48%